$23.46
-0.27 (-1.14%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TNDM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 4 observational · 12 with posted results
Held by 14 tracked-famous managers (CITADEL ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, Verition Fund Management LLC, Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., +9 more) · FINRA short interest 6.6 days to cover (settled 2026-07-31) · government filings 180d: 1 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in FranceNCT07211126observationalRate of diabetic ketoacidosis (DKA). | — | Recruiting | Device: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) | Diabetes Mellitus, Type 1 | 350 | Dec 2027 | ≤ 498 d | 2026-05-01 |
| Feasibility Study of Extended Wear Insulin Infusion Set Options During Home Use in People With Type 1 DiabetesNCT073254617 Day Survival of Infusion Set for Primary Outcome MeasureNon-randomized · Open-label · Treatment | Not applicable | Active, not recruiting | Device: SteadiSet Infusion Set | Diabetes Mellitus, Type 1 | 20 | 2027-03-01 | in 193 d | 2026-06-01 |
| PS230005 Control-IQ 1.5 Post-Approval StudyNCT06717451observationalIncidence Rates of Severe Hypoglycemia (SH) | — | Active, not recruiting | Device: Control-IQ Technology v1.5 | Type 1 Diabetes | 144 | 2026-08-11 | — | 2025-11-12 |
| Tandem Freedom - Feasibility Trial 2NCT06834568results2026-02-06Number of Participants With One or More Severe Hypoglycemia EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: t:slim X2 insulin pump with Tandem Freedom Algorithm | Diabetes Mellitus, Type 1 | 10 | 2025-04-07actual | — | 2026-05-05 |
| Investigational Extended Wear Insulin Infusion Set in People With Type 1 DiabetesNCT06273124results2025-09-247 Day Survival of Infusion Set for Primary Outcome Measure - HumalogOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: SteadiSet Extended Wear Infusion Set | Type1diabetes | 260 | 2024-12-11actual | — | 2025-09-24 |
| Sigi Insulin Management System - A First-in-Human Study in Adults With Type 1 DiabetesNCT05973422Serious Adverse EventsOpen-label · Device feasibility | Not applicable | Unknown status | Device: SIGI Insulin Management System | Type 1 Diabetes | 10 | 2024-09-30 | — | 2024-01-11 |
| A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 DiabetesNCT05785832results2025-06-03HbA1cRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM) | Type 2 Diabetes Treated With Insulin | 319 | 2024-09-24actual | — | 2026-05-22 |
| Tandem Freedom Feasibility Study 1NCT06428591results2025-11-18Severe Hypoglycemia EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: t:slim X2 insulin pump with Tandem Freedom Algorithm | Diabetes Mellitus, Type 1 | 10 | 2024-06-10actual | — | 2025-11-18 |
| Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 DiabetesNCT05683392results2024-12-20Number of Severe Hypoglycemic EventsRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ technology 2.0 | Type 1 Diabetes | 72 | 2023-12-13actual | — | 2024-12-20 |
| Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 DiabetesNCT05403502results2024-07-26Severe HypoglycemiaOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ technology 1.5 | Type 1 Diabetes | 183 | 2023-08-02actual | — | 2024-07-26 |
| Control-IQ Observational (CLIO) Post-Approval StudyNCT04503174results2023-12-08observationalIncidence Rates of Severe Hypoglycemia (SH)Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: t:slim X2 pump with Control-IQ technology | Diabetes Mellitus, Type 1 | 3,157 | 2023-06-02actual | — | 2023-12-08 |
| Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)NCT05422053results2024-04-17Number of Severe Hypoglycemic EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: t:slim X2 insulin pump with Control-IQ technology 1.5 | Type 1 Diabetes | 34 | 2023-01-06actual | — | 2025-04-03 |
| Adaptation of Insulin Delivery Settings to Improve Clinical Outcomes With AID UseNCT05204134results2024-04-05Severe Hypoglycemic EventsOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Automated Insulin Delivery Settings Initialization and Adaptation Algorithm | Type 1 Diabetes | 33 | 2022-09-09actual | — | 2024-04-05 |
| Control-IQ Technology in Individuals With Type 2 DiabetesNCT05111301results2024-03-06CGM Time Below 54 mg/dLNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Control-IQ technology 1.5 | Type 2 Diabetes Treated With Insulin | 30 | 2022-08-10actual | — | 2024-03-06 |
| Control-IQ Technology 2.0 Adult and Adolescent Feasibility StudyNCT05014789results2026-06-01Overall Percent Time Less Than 54 mg/dLOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Control-IQ technology 2.0 | Diabetes Mellitus, Type 1 | 66 | 2021-12-20actual | — | 2026-06-24 |
| Diabetes Pump With Predictive Low Glucose Suspend Pivotal TrialNCT03195140results2023-12-08Hypoglycemia < 70 mg/dLRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Predictive Low Glucose Suspend | Diabetes Mellitus, Type 1 | 103 | 2018-02-06actual | — | 2023-12-08 |
| Tandem Predictive Low Glucose Suspend Inpatient Feasibility StudyNCT02877771Suspension of Insulin DeliveryOpen-label | Phase 1 | Completed | Device: t:slim insulin pump with predictive low glucose suspend | Diabetes Mellitus, Type 1 Diabetes, Insulin Pump | 10 | Aug 2016actual | — | 2016-09-01 |
| Validation Study of G4 User InterfaceNCT01142895observational | — | Completed | — | Diabetes Mellitus | 33 | May 2010actual | — | 2010-06-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19